All In Biotech

Drug Trial Radar · NCT02209987

Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults

A Phase 1 Study to Evaluate the Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Oct 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Aug 2014

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will estimate the absolute bioavailability of subcutaneously injected GS-5745, characterize the safety, tolerability, and pharmacokinetics (PK) of GS-5745 after subcutaneous (SC) injection and intravenous (IV) administration, and evaluate the formation of anti-GS-5745 antibodies after SC and IV administration.

Conditions

  • Ulcerative Colitis

Interventions

  • GS-5745 SCDrug

    GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe

  • GS-5745 IVDrug

    GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK profile of GS-5745Time frame: Predose and postdose on Days 1 and Day 11, and Weeks 2, 3, 4, 6, and 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.